New hope for Tough-to-Treat lung cancer: experimental combo enters human testing
NCT ID NCT07113691
Summary
This early-stage study is testing the safety of a three-part treatment for extensive-stage small cell lung cancer that has persisted, returned, or worsened after standard therapy. The treatment combines a new drug called iadademstat with an existing immunotherapy (atezolizumab) and targeted radiation (SBRT). Researchers aim to see if this combination can better control the cancer while being tolerable for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.